BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: May 14, 2025 · CIK: 882796
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: BCRX
TL;DR
BioCryst filed a routine 8-K, no major news.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on May 14, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by BioCryst Pharmaceuticals, Inc. to the SEC, without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no indication of significant new risks or material adverse events.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- May 14, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of May 14, 2025.
What is the exact name of the registrant?
The exact name of the registrant is BioCryst Pharmaceuticals, Inc.
In which state was BioCryst Pharmaceuticals, Inc. incorporated?
BioCryst Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for BioCryst Pharmaceuticals, Inc.?
The principal executive office address is 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
Does this filing disclose any specific new material events or financial results?
Based on the provided text, this filing appears to be a standard reporting 8-K and does not explicitly disclose specific new material events or detailed financial results beyond the reporting categories.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).